1. Alexion says “no” to investor proactive sale demand — FDA approves first copycats of Novartis MS drug Gilenya — $178M stockpile of Merck ebola vaccine authorized — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Fallout

Discussion in 'Dendrite' started by Anonymous, Oct 10, 2012 at 3:17 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Heard there was bleeding occurring - what happened?
     

  2. Anonymous

    Anonymous Guest

    The DoucheBags who bought Dendrite for SEVEN HUNDRED FIFTY MILLION DOLLARS did not have the foresight to understand this product type was in the tail of it's product life cycle. This, coupled with the Pharma consolidations, R&D pipeline failures and patent cliffs do not make a Pharma CRM vendor so 'special' anymore. Customers are looking at Veeva as the leader in this narrow sector. Growth is not possible for now and unless they build some new compelling product, this shoppe will continue to just cut costs to survive. Doesnt look too promising.